Tomotake Shirono

1.3k total citations
50 papers, 704 citations indexed

About

Tomotake Shirono is a scholar working on Hepatology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Tomotake Shirono has authored 50 papers receiving a total of 704 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Hepatology, 15 papers in Surgery and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Tomotake Shirono's work include Hepatocellular Carcinoma Treatment and Prognosis (40 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers) and Cancer Mechanisms and Therapy (13 papers). Tomotake Shirono is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (40 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers) and Cancer Mechanisms and Therapy (13 papers). Tomotake Shirono collaborates with scholars based in Japan and South Korea. Tomotake Shirono's co-authors include Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takuji Torimura, Masahito Nakano, Hironori Koga, Ryoko Kuromatsu, Takumi Kawaguchi, Shusuke Okamura and Yu Noda and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Nutrients.

In The Last Decade

Tomotake Shirono

45 papers receiving 697 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomotake Shirono Japan 15 529 200 182 169 159 50 704
Shigeo Shimose Japan 17 641 1.2× 230 1.1× 246 1.4× 217 1.3× 214 1.3× 65 897
Shusuke Okamura Japan 16 558 1.1× 161 0.8× 206 1.1× 219 1.3× 191 1.2× 34 783
Ya-Hao Zhou China 15 710 1.3× 75 0.4× 415 2.3× 258 1.5× 199 1.3× 44 931
Jianhua Wang China 12 222 0.4× 76 0.4× 181 1.0× 149 0.9× 176 1.1× 42 589
Ciro Celsa Italy 17 334 0.6× 56 0.3× 427 2.3× 211 1.2× 223 1.4× 59 771
Kenya Yamanaka Japan 17 319 0.6× 45 0.2× 146 0.8× 327 1.9× 153 1.0× 42 711
Kiminori Uka Japan 9 418 0.8× 86 0.4× 147 0.8× 229 1.4× 149 0.9× 14 584
Carlos Castro Benítez France 19 692 1.3× 64 0.3× 239 1.3× 511 3.0× 400 2.5× 32 963
Yusuke Okuwaki Japan 14 503 1.0× 67 0.3× 300 1.6× 172 1.0× 68 0.4× 23 579

Countries citing papers authored by Tomotake Shirono

Since Specialization
Citations

This map shows the geographic impact of Tomotake Shirono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomotake Shirono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomotake Shirono more than expected).

Fields of papers citing papers by Tomotake Shirono

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomotake Shirono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomotake Shirono. The network helps show where Tomotake Shirono may publish in the future.

Co-authorship network of co-authors of Tomotake Shirono

This figure shows the co-authorship network connecting the top 25 collaborators of Tomotake Shirono. A scholar is included among the top collaborators of Tomotake Shirono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomotake Shirono. Tomotake Shirono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shimose, Shigeo, Takashi Niizeki, Hideki Iwamoto, et al.. (2025). Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria. Hepatology Research. 55(7). 1015–1025.
2.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2024). Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. Current Oncology. 31(10). 5821–5831. 1 indexed citations
3.
Iwamoto, Hideki, Takashi Niizeki, Tomotake Shirono, et al.. (2024). Case Reports of Pituitary Adrenocortical Insufficiency Following Atezolizumab+Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. Kanzo. 65(1). 37–44.
4.
Shimose, Shigeo, Hideki Iwamoto, Takashi Niizeki, et al.. (2023). Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching. International Journal of Molecular Sciences. 24(18). 13715–13715. 4 indexed citations
5.
Shimose, Shigeo, Hideki Iwamoto, Tomotake Shirono, et al.. (2023). The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Medicine. 12(11). 12325–12335. 14 indexed citations
6.
Shimose, Shigeo, Takashi Niizeki, Hideki Iwamoto, et al.. (2023). Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib. Journal of Gastroenterology and Hepatology. 38(7). 1140–1147. 4 indexed citations
7.
Kuromatsu, Ryoko, Tatsuya Ide, Shusuke Okamura, et al.. (2022). Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers. 14(9). 2295–2295. 5 indexed citations
8.
Shirono, Tomotake, Hideki Iwamoto, Takashi Niizeki, et al.. (2022). Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology Communications. 6(9). 2594–2604. 8 indexed citations
9.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2022). Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers. 14(17). 4284–4284. 11 indexed citations
10.
Iwamoto, Hideki, Shigeo Shimose, Yu Noda, et al.. (2021). Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers. 13(11). 2786–2786. 39 indexed citations
11.
Nakano, Masahito, Kazuta Fukumori, Yoichi Yano, et al.. (2021). Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers. 13(21). 5282–5282. 12 indexed citations
12.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2021). Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers. 13(1). 160–160. 37 indexed citations
13.
Kamachi, Naoki, Masahito Nakano, Shusuke Okamura, et al.. (2021). Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound. Cancer Reports. 5(2). e1471–e1471. 6 indexed citations
14.
Niizeki, Takashi, Hideki Iwamoto, Tomotake Shirono, et al.. (2021). Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers. 13(17). 4450–4450. 15 indexed citations
15.
Shirono, Tomotake, Takashi Niizeki, Hideki Iwamoto, et al.. (2021). Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine. 10(5). 987–987. 4 indexed citations
16.
Nakano, Masahito, Ryoko Kuromatsu, Takashi Niizeki, et al.. (2020). Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis. Hepatology Communications. 4(8). 1218–1228. 18 indexed citations
17.
Iwamoto, Hideki, Hiroyuki Suzuki, Shigeo Shimose, et al.. (2020). Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. Cancers. 12(4). 1010–1010. 44 indexed citations
18.
19.
Shimose, Shigeo, Hideki Iwamoto, Takashi Niizeki, et al.. (2020). Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers. 12(7). 1867–1867. 54 indexed citations
20.
Taguchi, Jun, Osamu Nakashima, Tomotake Shirono, et al.. (2010). A resected case of primary liver cancer, consisting of hepatocellular carcinoma and cholangiolocellular carcinoma, arising in alcoholic liver disease. Kanzo. 51(11). 664–673. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shigeo Shimose Breakdown of academic impact, for papers by Shusuke Okamura Breakdown of academic impact, for papers by Ya-Hao Zhou Breakdown of academic impact, for papers by Jianhua Wang Breakdown of academic impact, for papers by Ciro Celsa Breakdown of academic impact, for papers by Kenya Yamanaka Breakdown of academic impact, for papers by Kiminori Uka Breakdown of academic impact, for papers by Carlos Castro Benítez Breakdown of academic impact, for papers by Yusuke Okuwaki
Rankless by CCL
2026